Amlodipine Besylate

Amlodipine Besylate

Global Amlodipine Besylate Market to Reach US$1.3 Billion by 2030

The global market for Amlodipine Besylate estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 2.1% over the analysis period 2023-2030. High Blood Pressure Application, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$599.8 Million by the end of the analysis period. Growth in the Heart Disease Application segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$314.6 Million While China is Forecast to Grow at 4.3% CAGR

The Amlodipine Besylate market in the U.S. is estimated at US$314.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$261.3 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Amlodipine Besylate Market - Key Drivers and Trends Summarized

Amlodipine is a calcium channel blocker medication primarily used to treat high blood pressure (hypertension) and angina (chest pain). By inhibiting the influx of calcium ions into cardiac and smooth muscle cells, amlodipine helps relax and widen blood vessels, improving blood flow and reducing the heart`s workload. This mechanism of action makes it an effective treatment for preventing strokes, heart attacks, and other cardiovascular issues associated with hypertension. Available in various dosages, amlodipine is often prescribed as a once-daily oral tablet and can be used alone or in combination with other antihypertensive agents.

The use of amlodipine has expanded significantly since its introduction, with numerous studies validating its efficacy and safety. It is now one of the most commonly prescribed medications for managing hypertension globally. The drug`s popularity is partly due to its relatively mild side effect profile compared to other antihypertensives, making it suitable for long-term use. Moreover, the versatility of amlodipine, both as a monotherapy and in combination with other medications like ACE inhibitors or diuretics, has enhanced its utility in clinical practice. The development of generic versions of amlodipine has also made it more accessible and affordable, contributing to its widespread adoption. In addition to treating hypertension and angina, ongoing research is exploring potential new indications for amlodipine, such as its role in managing coronary artery disease and other cardiovascular conditions.

The growth in the amlodipine market is driven by several factors. Firstly, the increasing prevalence of hypertension and cardiovascular diseases worldwide has significantly boosted the demand for effective antihypertensive medications. Secondly, the aging global population, which is more prone to hypertension and related disorders, has further escalated the need for treatments like amlodipine. Additionally, the continuous advancement in pharmaceutical research has led to the development of improved formulations and combination therapies that enhance patient compliance and therapeutic outcomes. The expansion of healthcare infrastructure in emerging markets has also improved access to hypertension treatments, thereby driving market growth. Furthermore, strategic marketing efforts and educational initiatives by pharmaceutical companies have raised awareness about hypertension management, encouraging more patients to seek treatment. Finally, favorable regulatory environments and the increasing availability of generic versions have made amlodipine more accessible, contributing to its sustained market growth.

Select Competitors (Total 36 Featured) -

• Amsal Chem Pvt. Ltd.
• Apotex Inc.
• Cadila Pharmaceuticals Ltd.
• Century Pharmaceuticals Ltd.
• Changzhou Yabang Pharmaceutical Co. Ltd.
• Cipla Ltd
• Dr. Reddys Laboratories Ltd.
• Lupin Pharmaceuticals, Inc.
• Midas Pharma GmbH
• MOEHS IBERICA SL
• Orbion Pharmaceuticals Pvt. Ltd.
• Pfizer Inc.
• Strides Pharma Science Ltd
• Teva Pharmaceutical USA, Inc.
• Zydus Pharmaceuticals, Inc.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.